Detection of HPV DNA in Cervical Intraepithelial Neoplasia Using In Situ Hybridization.
In situ hybridization detected high-risk human papillomavirus genotypes with 86.36% sensitivity but low specificity
Detection of HPV DNA in Cervical Intraepithelial Neoplasia Using In Situ Hybridization.
Human papillomavirus (human papillomavirus)-related diseases remain a major global health problem, with cervical intraepithelial neoplasia (cervical intraepithelial neoplasia) representing a key precursor to cervical cancer.
This study aimed to evaluate the usefulness of in situ hybridization (ISH) for detecting human papillomavirus DNA in formalin-fixed, paraffin-embedded (FFPE) cervical tissue and to compare automated signal detection with manual histopathological assessment.
This prospective, non-randomized study included 83 women undergoing diagnostic procedures for abnormal cytology or confirmed cervical intraepithelial neoplasia between 2022 and 2023.
correctly flagged most high-risk human papillomavirus cases, but with many false positives
ISH II distribution was significantly associated with the presence of human papillomavirus type 6 or 11 ( p < 0.001), although stain structure itself was not.
ISH III stain structure was significantly associated with high-risk human papillomavirus genotypes ( p = 0.020).
Overall diagnostic accuracy was 63.86% for ISH II and 73.49% for ISH III.
ISH proved to be a reproducible method for detecting human papillomavirus in archived cervical tissue, enabling assessment even years after specimen collection.
Although PCR-based methods remain more widely used due to higher sensitivity and less invasive sampling, ISH provides valuable morphological context and may serve as a complementary diagnostic tool, particularly when only archival tissue is available.